Cannell & Co. purchased a new position in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 12,600 shares of the biopharmaceutical company’s stock, valued at approximately $267,000. Several other institutional investors have also […]
Xencor (NASDAQ:XNCR – Get Free Report) released its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of $0.36 by ($0.67), Briefing.com reports. Xencor had a negative net margin of 81.94% and a negative return on equity of 17.26%. The company had revenue of […]
Xencor (NASDAQ:XNCR – Get Free Report) posted its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of $0.36 by ($0.67), Briefing.com reports. The business had revenue of $44.70 million during the quarter, compared to the consensus estimate of $77.63 million. Xencor had a […]
Xencor (NASDAQ:XNCR – Get Free Report) announced its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of $0.36 by ($0.67), Briefing.com reports. The firm had revenue of $44.70 million during the quarter, compared to analyst estimates of $77.63 million. Xencor had a negative net margin […]
StockNews.com lowered shares of Xencor (NASDAQ:XNCR – Free Report) from a hold rating to a sell rating in a research report released on Thursday morning. XNCR has been the topic of a number of other research reports. Royal Bank of Canada cut their price objective on shares of Xencor from $36.00 to $32.00 and set […]